1Powell SF, Novello S, Garassino MC, et al. Effect of tumor size change and duration of response on overall survival with first-line pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non‒small-cell lung cancer. Poster presented at: North America Conference on Lung Cancer (NACLC Virtual); October 16-17, 2020.
2Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. https://doi.org/10.1056/nejmoa1801005
3Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer. J Clin Oncol. 2020;38(14):1505‐1517. https://doi.org/10.1200/jco.19.03136
4Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881-895. https://doi.org/10.1016/j.annonc.2021.04.008
5Gray JE, Rodriguez-Abreu D, Powell SF, et al. Pembrolizumab + pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189. Poster presented at: The International Association for the Study of Lung Cancer (IASLC) World Conference of Lung Cancer (WCLC Virtual); January 28-31, 2021.